<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">urovest</journal-id><journal-title-group><journal-title xml:lang="ru">Вестник урологии</journal-title><trans-title-group xml:lang="en"><trans-title>Urology Herald</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2308-6424</issn><publisher><publisher-name>Rostov State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21886/2308-6424-2024-12-5-45-54</article-id><article-id custom-type="elpub" pub-id-type="custom">urovest-957</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Экспрессия рецепторов ангиотензина II второго типа и синдекана-1 при раке предстательной железы</article-title><trans-title-group xml:lang="en"><trans-title>Expression of angiotensin II type 2 receptors and syndecan-1 in prostate cancer</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5128-4910</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Черногубова</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Chernogubova</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Черногубова Елена Александровна — канд. биол. наук.</p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Elena A. Chernogubova —Cand.Sc.(Biol).</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">eachernogubova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7748-0039</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Аветян</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Avetyan</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Аветян Андрей Владимирович.</p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Andrey V. Avetyan.</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">arsenalfvo@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2765-7910</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чибичян</surname><given-names>М. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Chibichyan</surname><given-names>M. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Чибичян Микаел Бедросович — д-р мед. наук, доцент.</p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Mikael B. Chibichyan —Dr.Sc.(Med), Assoc.Prof.(Docent).</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">michel_dept@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Коган</surname><given-names>М. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kogan</surname><given-names>M. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Коган Михаил Иосифович — д-р мед. наук, профессор, заслуженный деятель науки РФ.</p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Mikhail I. Kogan — Dr.Sc.(Med), Full Prof., Hons. Sci. of the Russian Federation.</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">dept_kogan@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральный исследовательский центр Южный научный центр Российской академии наук</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal Research Centre the Southern Scientific Centre of the Russian Academy of Sciences</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Ростовский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Rostov State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Федеральный исследовательский центр Южный научный центр Российской академии наук; Ростовский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal Research Centre the Southern Scientific Centre of the Russian Academy of Sciences; Rostov State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>28</day><month>11</month><year>2024</year></pub-date><volume>12</volume><issue>5</issue><fpage>45</fpage><lpage>54</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Черногубова Е.А., Аветян А.В., Чибичян М.Б., Коган М.И., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Черногубова Е.А., Аветян А.В., Чибичян М.Б., Коган М.И.</copyright-holder><copyright-holder xml:lang="en">Chernogubova E.A., Avetyan A.V., Chibichyan M.B., Kogan M.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.urovest.ru/jour/article/view/957">https://www.urovest.ru/jour/article/view/957</self-uri><abstract><sec><title>Введение</title><p>Введение. Рак предстательной железы (РПЖ) остаётся актуальной проблемой современной онкоурологии в связи с высокими показателями заболеваемости и смертности.</p></sec><sec><title>Цель исследования</title><p>Цель исследования. Оценить экспрессию рецепторов ангиотензина II второго типа (AT2-R) и синдекана-1 (CD138) при простатической интраэпителиальной неоплазии (ПИН) и раке предстательной железы.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Для иммуногистохимического (ИГХ) исследования использован материал полифокальных пункционных биопсий 20 мужчин: 10 мужчин — с ПИН-3, 10 мужчин — с РПЖ. Для ИГХ окрашивания использованы первичные антитела к AT2-R и антитела CD138 (клон MI 15), система визуализации EnVision FLEX. Постановка ИГХ реакций, интерпретация полученных результатов проведена по общепринятым правилам.</p></sec><sec><title>Результаты</title><p>Результаты. Результаты исследования показали, что дефицит AT2-R увеличивается в ряду ПИН-3 — РПЖ. В опухолевых клетках при РПЖ отмечалась слабая экспрессия AT2-R либо её отсутствие, при этом локализация рецептора AT2-R — ядерная. При ПИН-3 экспрессия синдекана-1 локализовалась на мембране базальных клеток и базолатеральной стороне секреторных эпителиальных клеток, без экспрессии в прилегающей строме, при этом уровень экспрессии синдекана-1 всегда оставался высоким. При РПЖ мембранная экспрессия синдекана-1 сохранялась. При уменьшении или отсутствии ядерной экспрессии AT2-R в ткани рака простаты с повышением ISUP уровень экспрессии синдекана-1 снижался.</p></sec><sec><title>Заключение</title><p>Заключение. Впервые показано одновременное снижение уровней экспрессии AT2-R и синдекана-1 при РПЖ. Комплексное определение уровней экспрессии рецепторов ангиотензина II второго типа и синдекана-1 является, по-видимому, перспективным для разработки диагностических и прогностических маркеров инициации и развития рака предстательной железы.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Prostate cancer (PCa) remains an urgent problem of modern oncological urology due to high morbidity and mortality rates.</p></sec><sec><title>Objective</title><p>Objective. To evaluate the expression of angiotensin II type 2 receptor (AT2-R) and syndecan-1 (CD138) receptors in prostatic intraepithelial neoplasia (PIN) and PCa.</p></sec><sec><title>Materials &amp; methods</title><p>Materials &amp; methods. For the immunohistochemical (IHC) study, the prostate biopsy cores of 20 men was used: 10 men with PIN, 10 men with PCa. Primary antibodies to AT2-R and CD138 antibodies were used for IHC staining, the EnVision FLEX imaging system. Formulation of IHC reactions, interpretation of the results obtained were carried out according to generally accepted rules.</p></sec><sec><title>Results</title><p>Results. The results of the study showed that AT2-R deficiency increases in the range of PIN-3 – PCa. Mild AT2-R expression or its absence was noted in tumor cells with PCa, while the AT2-R localisation was nuclear. In PIN-3, the expression of syndecan-1 was localised on the membrane of basal cells and the basolateral side of secretory epithelial cells, without expression in the adjacent stroma, while the expression level of syndecan-1 always remained high. In PCa, the membrane expression of syndecan-1 was preserved. With a decrease or absence of AT2-R nuclear expression in PCa tissue with an increase in ISUP, the expression level of syndecan-1 decreased.</p></sec><sec><title>Conclusion</title><p>Conclusion. Simultaneous decrease in the expression levels of AT2-R and syndecan-1 in PCa has been demonstrated for the first time. A comprehensive determination of the expression levels of AT2-R and syndecan-1 seems to be promising for the development of diagnostic and prognostic markers of PCa initiation and development.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>рак предстательной железы</kwd><kwd>простатическая интраэпителиальная неоплазия</kwd><kwd>рецепторы ангиотензина II второго типа</kwd><kwd>синдекан-1</kwd></kwd-group><kwd-group xml:lang="en"><kwd>prostate cancer</kwd><kwd>prostatic intraepithelial neoplasia</kwd><kwd>angiotensin II type 2 receptors</kwd><kwd>syndecan-1</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Публикация подготовлена в рамках реализации Государственного задания ЮНЦ РАН, № госрегистрации 122020100304-5.</funding-statement><funding-statement xml:lang="en">The publication was prepared as part of the State assignment of the Federal Research Center the Southern Scientific Centre of the Russian Academy of Sciences (State Registration No. 122020100304-5).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Злокачественные новообразования в России в 2023 году (заболеваемость и смертность). Под ред. Каприна А.Д., Старинского В.В., Шахзадовой А.О. М.: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2024.</mixed-citation><mixed-citation xml:lang="en">Kaprin A.D., Starinsky V.V., Shakhzadova A.O. Malignant tumors in Russia in 2021 (morbidity and mortality). Moscow: P.A. Gertsen Moscow Research Oncological Institute, Branch of the Federal State Budgetary Institution “National Medical Research Radiological Center” of the Ministry of Health of Russia; 2024. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. Erratum in: CA Cancer J Clin. 2024;74(2):203. DOI: 10.3322/caac.21820</mixed-citation><mixed-citation xml:lang="en">Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. Erratum in: CA Cancer J Clin. 2024;74(2):203. DOI: 10.3322/caac.21820</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Красняк С.С. Патогенетическая терапия доброкачественной гиперплазии предстательной железы и простатической интраэпителиальной неоплазии. Экспериментальная и клиническая урология. 2020(4):66-74. DOI: 10.29188/2222-8543-2020-13-4-66-74</mixed-citation><mixed-citation xml:lang="en">Krasnyak S.S. Pathogenetic therapy of benign prostatic hyperplasia and prostatic intraepithelial neoplasia. Experimental and Clinical Urology. 2020(4):66-74. (In Russian). DOI: 10.29188/2222-8543-2020-13-4-66-74</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Коган М.И., Ахохов З.М., Черногубова Е.А., Гусев А.А., Ойтова З.Х. Ренин-ангиотензиновая система: роль в развитии и прогрессии почечно-клеточного рака (обзор литературы). Онкоурология. 2019;15(3):143-149. DOI: 10.17650/1726-9776-2019-15-3-143-149</mixed-citation><mixed-citation xml:lang="en">Kogan M.I., Akhokhov Z.M., Chernogubova E.A., Gusev A.A., Oitova Z.Kh. The role of the renin-angiotensin system in the appearance and progression of renal cell carcinoma: a literature review. Cancer Urology. 2019;15(3):143-149. (In Russian). DOI: 10.17650/1726-9776-2019-15-3-143-149</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Чибичян М.Б., Черногубова Е.А., Аветян А.В., Лаптева Т.О., Павленко И.А., Коган М.И. Роль ангиотензинпревращающего фермента и рецепторов ангиотензина II второго типа в патогенезе пролиферативных заболеваний предстательной железы. Урология. 2022;(1): 5-10. DOI: 10.18565/urology.2022.1.5-10</mixed-citation><mixed-citation xml:lang="en">Chibichyan M.B., Chernogubova E.A., Avetyan A.V., Lapteva T.O., Pavlenko I.A., Kogan M.I. The role of angiotensin-converting enzyme and angiotensin ii receptors of the second type in the pathogenesis of proliferative diseases of the prostate. Urologiia. 2022;(1):5-10. (In Russian). DOI: 10.18565/urology.2022.1.5-10</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Domińska K, Lachowicz-Ochedalska A. Zaangazowanie układu renina-angiotensyna (RAS) w proces kancerogenezy [The involvement of the renin-angiotensin system (RAS) in cancerogenesis]. Postepy Biochem. 2008;54(3):294-300. (In Polish). PMID: 19112828</mixed-citation><mixed-citation xml:lang="en">Domińska K, Lachowicz-Ochedalska A. Zaangazowanie układu renina-angiotensyna (RAS) w proces kancerogenezy [The involvement of the renin-angiotensin system (RAS) in cancerogenesis]. Postepy Biochem. 2008;54(3):294-300. (In Polish). PMID: 19112828</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Wolgien MCGM, Correa SAA, Breuel PAF, Nazário ACP, Facina G. Renin Angiotensin System Components and Cancer:Reports of Association. J. Biosci. Med. 2016;(4):65–75. DOI: 10.4236/jbm.2016.45007</mixed-citation><mixed-citation xml:lang="en">Wolgien MCGM, Correa SAA, Breuel PAF, Nazário ACP, Facina G. Renin Angiotensin System Components and Cancer:Reports of Association. J. Biosci. Med. 2016;(4):65–75. DOI: 10.4236/jbm.2016.45007</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">D’Ardes D, Boccatonda A, Rossi I, Guagnano MT, Santilli F, Cipollone F, Bucci M. COVID-19 and RAS: Unravelling an Unclear Relationship. Int J Mol Sci. 2020;21(8):3003. DOI: 10.3390/ijms21083003</mixed-citation><mixed-citation xml:lang="en">D’Ardes D, Boccatonda A, Rossi I, Guagnano MT, Santilli F, Cipollone F, Bucci M. COVID-19 and RAS: Unravelling an Unclear Relationship. Int J Mol Sci. 2020;21(8):3003. DOI: 10.3390/ijms21083003</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Teng YH, Aquino RS, Park PW. Molecular functions of syndecan-1 in disease. Matrix Biol. 2012;31(1):3-16. DOI: 10.1016/j.matbio.2011.10.001</mixed-citation><mixed-citation xml:lang="en">Teng YH, Aquino RS, Park PW. Molecular functions of syndecan-1 in disease. Matrix Biol. 2012;31(1):3-16. DOI: 10.1016/j.matbio.2011.10.001</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lazniewska J, Li KL, Johnson IRD, Sorvina A, Logan JM, Martini C, Moore C, Ung BS, Karageorgos L, Hickey SM, Prabhakaran S, Heatlie JK, Brooks RD, Huzzell C, Warnock NI, Ward MP, Mohammed B, Tewari P, Martin C, O’Toole S, Edgerton LB, Bates M, Moretti P, Pitson SM, Selemidis S, Butler LM, O’Leary JJ, Brooks DA. Dynamic interplay between sortilin and syndecan-1 contributes to prostate cancer progression. Sci Rep. 2023;13(1):13489. DOI: 10.1038/s41598-023-40347-7</mixed-citation><mixed-citation xml:lang="en">Lazniewska J, Li KL, Johnson IRD, Sorvina A, Logan JM, Martini C, Moore C, Ung BS, Karageorgos L, Hickey SM, Prabhakaran S, Heatlie JK, Brooks RD, Huzzell C, Warnock NI, Ward MP, Mohammed B, Tewari P, Martin C, O’Toole S, Edgerton LB, Bates M, Moretti P, Pitson SM, Selemidis S, Butler LM, O’Leary JJ, Brooks DA. Dynamic interplay between sortilin and syndecan-1 contributes to prostate cancer progression. Sci Rep. 2023;13(1):13489. DOI: 10.1038/s41598-023-40347-7</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y, McKown RL, Raab RW, Rapraeger AC, Laurie GW. Focus on molecules: syndecan-1. Exp Eye Res. 2011;93(4):329-330. DOI: 10.1016/j.exer.2010.06.008</mixed-citation><mixed-citation xml:lang="en">Zhang Y, McKown RL, Raab RW, Rapraeger AC, Laurie GW. Focus on molecules: syndecan-1. Exp Eye Res. 2011;93(4):329-330. DOI: 10.1016/j.exer.2010.06.008</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Chaudhary PK, Kim S. An Insight into GPCR and G-Proteins as Cancer Drivers. Cells. 2021;10(12):3288. DOI: 10.3390/cells10123288</mixed-citation><mixed-citation xml:lang="en">Chaudhary PK, Kim S. An Insight into GPCR and G-Proteins as Cancer Drivers. Cells. 2021;10(12):3288. DOI: 10.3390/cells10123288</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmad Fauzi MF, Wan Ahmad WSHM, Jamaluddin MF, Lee JTH, Khor SY, Looi LM, Abas FS, Aldahoul N. Allred Scoring of ER-IHC Stained Whole-Slide Images for Hormone Receptor Status in Breast Carcinoma. Diagnostics (Basel). 2022;12(12):3093. DOI: 10.3390/diagnostics12123093</mixed-citation><mixed-citation xml:lang="en">Ahmad Fauzi MF, Wan Ahmad WSHM, Jamaluddin MF, Lee JTH, Khor SY, Looi LM, Abas FS, Aldahoul N. Allred Scoring of ER-IHC Stained Whole-Slide Images for Hormone Receptor Status in Breast Carcinoma. Diagnostics (Basel). 2022;12(12):3093. DOI: 10.3390/diagnostics12123093</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М.: МедиаСфера; 2002.</mixed-citation><mixed-citation xml:lang="en">Rebrova O.Ju. Statistical analysis of medical data. Using the STATISTICA Application Package. Moscow: MediaSfera; 2002. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press. 2003;12(2):70-88. DOI: 10.1080/08037050310001057</mixed-citation><mixed-citation xml:lang="en">Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press. 2003;12(2):70-88. DOI: 10.1080/08037050310001057</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Singh KD, Karnik SS. Angiotensin Receptors: Structure, Function, Signaling and Clinical Applications. J Cell Signal. 2016;1(2):111. DOI: 10.4172/jcs.1000111</mixed-citation><mixed-citation xml:lang="en">Singh KD, Karnik SS. Angiotensin Receptors: Structure, Function, Signaling and Clinical Applications. J Cell Signal. 2016;1(2):111. DOI: 10.4172/jcs.1000111</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Septiadi SS, Noegroho BS, Tjahjodjati T, Safriadiet F., Siregar S, Adriansjahal R, Adi K, Si-hombing AT, Pramod SV, Nasution R, Hernowo BS. Angiotensin II type-1 receptor (AT1R) distribution in BPH, high grade PIN and adenocarcinoma of the prostate. Indonesian Journal of Urology. 2010;17(2):55-57. DOI: 10.32421/juri.v17i2.348</mixed-citation><mixed-citation xml:lang="en">Septiadi SS, Noegroho BS, Tjahjodjati T, Safriadiet F., Siregar S, Adriansjahal R, Adi K, Si-hombing AT, Pramod SV, Nasution R, Hernowo BS. Angiotensin II type-1 receptor (AT1R) distribution in BPH, high grade PIN and adenocarcinoma of the prostate. Indonesian Journal of Urology. 2010;17(2):55-57. DOI: 10.32421/juri.v17i2.348</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Santos NJ, Barquilha CN, Barbosa IC, Macedo RT, Lima FO, Justulin LA, Barbosa GO, Carvalho HF, Felisbino SL. Syndecan Family Gene and Protein Expression and Their Prognostic Values for Prostate Cancer. Int J Mol Sci. 2021;22(16):8669. DOI: 10.3390/ijms22168669</mixed-citation><mixed-citation xml:lang="en">Santos NJ, Barquilha CN, Barbosa IC, Macedo RT, Lima FO, Justulin LA, Barbosa GO, Carvalho HF, Felisbino SL. Syndecan Family Gene and Protein Expression and Their Prognostic Values for Prostate Cancer. Int J Mol Sci. 2021;22(16):8669. DOI: 10.3390/ijms22168669</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Logan JM, Martini C, Sorvina A, Johnson IRD, Brooks RD, Caruso MC, Huzzell C, Moore CR, Karageorgos L, Butler LM, Tewari P, Prabhakaran S, Hickey SM, Klebe S, Samaratunga H, Delahunt B, Moretti K, O’Leary JJ, Brooks DA, Ung BS. Reinterpretation of prostate cancer pathology by Appl1, Sortilin and Syndecan-1 biomarkers. Sci Data. 2024;11(1):852. DOI: 10.1038/s41597-024-03696-0</mixed-citation><mixed-citation xml:lang="en">Logan JM, Martini C, Sorvina A, Johnson IRD, Brooks RD, Caruso MC, Huzzell C, Moore CR, Karageorgos L, Butler LM, Tewari P, Prabhakaran S, Hickey SM, Klebe S, Samaratunga H, Delahunt B, Moretti K, O’Leary JJ, Brooks DA, Ung BS. Reinterpretation of prostate cancer pathology by Appl1, Sortilin and Syndecan-1 biomarkers. Sci Data. 2024;11(1):852. DOI: 10.1038/s41597-024-03696-0</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Леонова Е.И. Галзитская О.В. Сравнительная характеристика структуры и функции синдекана-1 позвоночных животных. Молекулярная биология. 2013;47(3):505-512. DOI: 10.7868/S0026898413030075</mixed-citation><mixed-citation xml:lang="en">Leonova E.I., Galzitskaya O.V. Comparative characteristics of the structure and function for animal syndecan-1 proteins. Molecular Biology. 2013;47(3): 505-512. (In Russian). DOI: 10.7868/S0026898413030075</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Kind S, Kluth M, Hube-Magg C, Möller K, Makrypidi-Fraune G, Lutz F, Lennartz M, Rico SD, Schlomm T, Heinzer H, Höflmayer D, Weidemann S, Uhlig R, Huland H, Graefen M, Bernreuther C, Tsourlakis MC, Minner S, Dum D, Hinsch A, Lübke AM, Simon R, Sauter G, Marx A, Polonski A. Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence. Biomed Res Int. 2020;2020:5845374. DOI: 10.1155/2020/5845374</mixed-citation><mixed-citation xml:lang="en">Kind S, Kluth M, Hube-Magg C, Möller K, Makrypidi-Fraune G, Lutz F, Lennartz M, Rico SD, Schlomm T, Heinzer H, Höflmayer D, Weidemann S, Uhlig R, Huland H, Graefen M, Bernreuther C, Tsourlakis MC, Minner S, Dum D, Hinsch A, Lübke AM, Simon R, Sauter G, Marx A, Polonski A. Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence. Biomed Res Int. 2020;2020:5845374. DOI: 10.1155/2020/5845374</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Szarvas T, Sevcenco S, Módos O, Keresztes D, Nyirády P, Kubik A, Romics M, Kovalszky I, Reis H, Hadaschik B, Shariat SF, Kramer G. Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer. Urol Oncol. 2018;36(6):312.e9-312.e15. DOI: 10.1016/j.urolonc.2018.03.010</mixed-citation><mixed-citation xml:lang="en">Szarvas T, Sevcenco S, Módos O, Keresztes D, Nyirády P, Kubik A, Romics M, Kovalszky I, Reis H, Hadaschik B, Shariat SF, Kramer G. Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer. Urol Oncol. 2018;36(6):312.e9-312.e15. DOI: 10.1016/j.urolonc.2018.03.010</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Shimada K, Anai S, Fujii T, Tanaka N, Fujimoto K, Konishi N. Syndecan-1 (CD138) contributes to prostate cancer progression by stabilizing tumour-initiating cells. J Pathol. 2013;231(4):495-504. DOI: 10.1002/path.4271</mixed-citation><mixed-citation xml:lang="en">Shimada K, Anai S, Fujii T, Tanaka N, Fujimoto K, Konishi N. Syndecan-1 (CD138) contributes to prostate cancer progression by stabilizing tumour-initiating cells. J Pathol. 2013;231(4):495-504. DOI: 10.1002/path.4271</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Коган М.И., Черногубова Е.А., Чибичян М.Б., Матишов Д.Г. Ангиотензинпревращающий фермент — новый прогностический маркер рецидива при терапии рака предстательной железы. Онкоурология. 2016;12(4):87-93. DOI: 10.17650/1726-9776-2016-12-4-87-93</mixed-citation><mixed-citation xml:lang="en">Kogan M.I., Chernogubova E.A., Chibichyan M.B., Matishov D.G. Angiotensin converting enzyme — a new prognostic marker of recurrence in the treatment of prostate cancer. Cancer Urology. 2016;12(4):87-93. (In Russian). DOI: 10.17650/1726-9776-2016-12-4-87-93</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Чибичян М.Б., Коган М.И., Черногубова Е.А., Павленко И.А. Матишов Д.Г. Роль рецепторов ангиотензина II второго типа в прогнозировании биохимического рецидива при терапии рака предстательной железы. Урология. 2016;(6):89-94.</mixed-citation><mixed-citation xml:lang="en">Chibichyan M.B., Kogan M.I., Chernogubova E.A. et al. Role of angiotensin II receptor type 2 in predicting biochemical recurrence in the treatment of prostate cancer. Urologiia. 2016;(6):89-94. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Csermely P, Korcsmáros T, Kiss HJ, London G, Nussinov R. Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review. Pharmacol Ther. 2013;138(3):333-408. DOI: 10.1016/j.pharmthera.2013.01.016</mixed-citation><mixed-citation xml:lang="en">Csermely P, Korcsmáros T, Kiss HJ, London G, Nussinov R. Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review. Pharmacol Ther. 2013;138(3):333-408. DOI: 10.1016/j.pharmthera.2013.01.016</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Шпаков А.О. Ангиотензинпревращающий фермент 2-го типа, как молекулярный посредник для инфицирования клетки вирусами SARS-Cov и SARS-Cov-2. Российский физиологический журнал им. И.М. Сеченова. 2020;106(6):795-810. DOI: 10.31857/S086981392006013</mixed-citation><mixed-citation xml:lang="en">Shpakov A.O. Angiotensin-Converting Enzyme of the Type 2 as a Molecular Mediator for the Entry of SARS-Cov and SARS-Cov-2 Viruses into the Cell. Russian Journal of Physiology. 106(6):795–810. (In Russian). DOI: 10.31857/S086981392006013</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Sehn F, Büttner H, Godau B, Müller M, Sarcan S, Offermann A, Perner S, Kramer MW, Merseburger AS, Roesch MC. The alternative renin-angiotensin-system (RAS) signalling pathway in prostate cancer and its link to the current COVID-19 pandemic. Mol Biol Rep. 2023;50(2):1809-1816. DOI: 10.1007/s11033-022-08087-5</mixed-citation><mixed-citation xml:lang="en">Sehn F, Büttner H, Godau B, Müller M, Sarcan S, Offermann A, Perner S, Kramer MW, Merseburger AS, Roesch MC. The alternative renin-angiotensin-system (RAS) signalling pathway in prostate cancer and its link to the current COVID-19 pandemic. Mol Biol Rep. 2023;50(2):1809-1816. DOI: 10.1007/s11033-022-08087-5</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Gujrati H, Ha S, Wang BD. Deregulated microRNAs Involved in Prostate Cancer Aggressiveness and Treatment Resistance Mechanisms. Cancers (Basel). 2023;15(12):3140. DOI: 10.3390/cancers15123140</mixed-citation><mixed-citation xml:lang="en">Gujrati H, Ha S, Wang BD. Deregulated microRNAs Involved in Prostate Cancer Aggressiveness and Treatment Resistance Mechanisms. Cancers (Basel). 2023;15(12):3140. DOI: 10.3390/cancers15123140</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Имянитов Е.Н. Эпидемиология и биология рака простаты. Практическая онкология. 2008;9(2):57-64. eLIBRARY ID: 19130354; EDN: QCQJKL</mixed-citation><mixed-citation xml:lang="en">Imyanitov E.N. Epidemiology and biology of prostate cancer. Practical oncology. 2008;9(2):57-64. (In Russian). eLIBRARY ID: 19130354; EDN: QCQJKL</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou J, Du T, Li B, Rong Y, Verkhratsky A, Peng L. Crosstalk Between MAPK/ERK and PI3K/AKT Signal Pathways During Brain Ischemia/ Reperfusion. ASN Neuro. 2015;7(5):1759091415602463. DOI: 10.1177/1759091415602463</mixed-citation><mixed-citation xml:lang="en">Zhou J, Du T, Li B, Rong Y, Verkhratsky A, Peng L. Crosstalk Between MAPK/ERK and PI3K/AKT Signal Pathways During Brain Ischemia/ Reperfusion. ASN Neuro. 2015;7(5):1759091415602463. DOI: 10.1177/1759091415602463</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Butler DE, Marlein C, Walker HF, Frame FM, Mann VM, Simms MS, Davies BR, Collins AT, Maitland NJ. Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer. Oncotarget. 2017;8(34):56698-56713. DOI: 10.18632/oncotarget.18082</mixed-citation><mixed-citation xml:lang="en">Butler DE, Marlein C, Walker HF, Frame FM, Mann VM, Simms MS, Davies BR, Collins AT, Maitland NJ. Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer. Oncotarget. 2017;8(34):56698-56713. DOI: 10.18632/oncotarget.18082</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Shorning BY, Dass MS, Smalley MJ, Pearson HB. The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling. Int J Mol Sci. 2020;21(12):4507. DOI: 10.3390/ijms21124507</mixed-citation><mixed-citation xml:lang="en">Shorning BY, Dass MS, Smalley MJ, Pearson HB. The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling. Int J Mol Sci. 2020;21(12):4507. DOI: 10.3390/ijms21124507</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Sadrkhanloo M, Paskeh MDA, Hashemi M, Raesi R, Motahhary M, Saghari S, Sharifi L, Bokaie S, Mirzaei S, Entezari M, Aref AR, Salimimoghadam S, Rashidi M, Taheriazam A, Hushmandi K. STAT3 signaling in prostate cancer progression and therapy resistance: An oncogenic pathway with diverse functions. Biomed Pharmacother. 2023;158:114168. DOI: 10.1016/j.biopha.2022.114168</mixed-citation><mixed-citation xml:lang="en">Sadrkhanloo M, Paskeh MDA, Hashemi M, Raesi R, Motahhary M, Saghari S, Sharifi L, Bokaie S, Mirzaei S, Entezari M, Aref AR, Salimimoghadam S, Rashidi M, Taheriazam A, Hushmandi K. STAT3 signaling in prostate cancer progression and therapy resistance: An oncogenic pathway with diverse functions. Biomed Pharmacother. 2023;158:114168. DOI: 10.1016/j.biopha.2022.114168</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, Ewing CM, Platz EA, Ferdinandusse S, Wanders RJ, Trent JM, Isaacs WB, De Marzo AM. Alphamethylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 2002;62(8):2220-2226. PMID: 11956072</mixed-citation><mixed-citation xml:lang="en">Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, Ewing CM, Platz EA, Ferdinandusse S, Wanders RJ, Trent JM, Isaacs WB, De Marzo AM. Alphamethylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 2002;62(8):2220-2226. PMID: 11956072</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
